

# Gastrointestinal System

H2 Blockers, PPIs, Anti-Emetics
















### Gastroesophageal Reflux Disease (GERD)



### Peptic ulcer (Stomach/duodenal ulcers)



### Acid secretion regulation





Fig. 51-2. Parietal cell stimulation and secretion. ADP, Adenosine diphosphate; ATP, adenosine triphosphate; ATPase, adenosine triphosphatase; cAMP, cyclic adenosine monophosphate.

G-cells (antrum) → produce gastrin. D-cells protect stomach from overproduction of gastric acid by releasing somatostatin (SST) → inhibits production of gastrin. ACh and gastrin → increase release of histamine-2 from enterochromaffin-like (ECL) cells. Gastrin, Histamine-2, ACh (acetylcholine) → bind to receptors on parietal cells → gastric acid secretion







# Antacids











## Antacids (Maalox, Mylanta)

- Onset: immediate (minutes)
- Duration: 30 minutes on an empty stomach, but 3 hours when taken within 1 hour of meals
- Alginic acid may be added to antacids → forms a viscous solution that floats on top of gastric contents → protects the esophageal mucosa from acid reflux
- Simethicone (surfactant) may be added to antacids → "breaks up" gas bubbles → relieves gas
- Caution: small amounts of aluminum and magnesium are absorbed and can accumulate in renal insufficiency → toxicity
  - Magnesium: avoid in patients with  $\text{CrCl} < 30 \text{ ml/min}$
  - Aluminum: avoid in patients with renal failure ( $\text{CrCl} < 15 \text{ ml/min}$ )



Antacids (cont.)

## Sodium Bicarbonate (Alka-Seltzer)

High sodium content (567 mg per tablet) →  $\text{Na}^+/\text{H}_2\text{O}$  retention  
→ exacerbates hypertension, heart failure, chronic kidney disease



# Proton Pump Inhibitors (PPIs)

















# Anti-Emetics





























# Study Checks

























- What are the **serious adverse drug reactions of PPIs?**

Long-Term SEs of PPIs (usually with high doses)

- Atrophic gastritis has been “rarely” associated with patients on long-term therapy PPIs for *Helicobacter pylori*.
- Risk of *C. difficile* and other enteric infections has been observed due to ability of pathogens to survive in a less acidic GI environment; however the overall risk is low.
- Vit B<sub>12</sub> deficiency, since gastric acid is required to extract Vit B<sub>12</sub> from dietary sources. Monitor Vit B12 levels in PPI patients.
- Hypomagnesemia may occur with long-term use of PPIs due to reduced intestinal absorption. Monitoring serum magnesium levels is recommended in patients on long-term PPI therapy.
- Hypocalcemia and increase risk of fractures is associated with reduced calcium absorption due to hypochlorhydria. Since calcium citrate does not require acid for absorption, it is the recommended calcium supplement in patients on long-term PPI therapy.
- Iron malabsorption secondary to long-term gastric acid suppression with PPIs, however this does not appear to be of clinical significance unless a patient requires oral iron supplementation. Higher doses and longer duration of iron supplementation are recommended in these patients.


# References

1. Brunton LL, Knollmann BC, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. Fourteenth edition. McGraw Hill; 2023.
2. Golan DE, Armstrong EJ, Armstrong AW, eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4. Edition. Wolters Kluwer; 2017.
3. Papadakis, M., Rabow, M., McQuaid, K., & Gandhi, M. (2024). CURRENT medical diagnosis and treatment 2025 (64th ed.). Columbus, OH: McGraw-Hill Education.
4. Whalen K, Lerchenfeldt S, Giordano CR, eds. Pharmacology. Eighth edition. Wolters Kluwer Health; 2023.

# Sucralfate (Carafate)

(cytoprotective agent)

MOA: binds to gastric ulcer forming a protective barrier



## Sucralfate (Carafate)

- Sucralfate may also have protective effect by stimulating release of mucosal prostaglandins (PGE)
- SE: constipation (1-3%) due to aluminum content
- Caution: aluminum content may accumulate in patients with renal insufficiency → “aluminum encephalopathy” (i.e., dementia), and anemia
- Aluminum binds dietary phosphate (GI tract) → hypophosphatemia
- Sucralfate tablets are large and may be difficult for geriatrics to swallow → use liquid formulation





## Misoprostol (Cytotec)

MOA: synthetic prostaglandin (PG) analog

- stimulates the production of mucus and bicarbonate (“mucoprotective shield”)
- improves mucosal blood flow
- reduces mucosal cell turnover
- mildly inhibits gastric acid secretion (less than H<sub>2</sub>RAs)

SE: diarrhea (up to 30%), abdominal cramping

- take with food and reduce daily dose to minimize incidence of diarrhea

Caution: misoprostol is contraindicated in pregnancy.

- use in women in childbearing years requires negative serum pregnancy test and adequate contraception



## Antiemetic Agents

There are 4 major sources of afferent input to the vomiting center.

- (1) CTZ (chemoreceptor trigger zone)
  - located outside the BBB and is subject to stimuli in blood
  - receptors: D<sub>2</sub>, opioid, 5-HT<sub>3</sub>, NK<sub>1</sub>
- (2) Vestibular System
  - important in motion sickness
  - receptors: M<sub>1</sub> and H<sub>1</sub>
- (3) Vagal and Spinal Afferent Nerves from the GI tract
  - receptors: 5-HT<sub>3</sub>
  - GI irritates (chemotherapy, distention, infection)
    - release of mucosal serotonin
    - activate 5-HT<sub>3</sub> receptors
    - propagate vagal afferent impulses to vomiting center and CTZ
- (4) Central Nervous System (CNS)
  - stress, psychiatric disorders, anticipatory vomiting, etc...





FIGURE 62-6 Neurologic pathways involved in pathogenesis of nausea and vomiting (see text). (Modified and reproduced, with permission, from Krakauer EL et al: Case records of the Massachusetts General Hospital. N Engl J Med 2005;352:817.)

### Serotonin 5-HT<sub>3</sub> Antagonists

- **Ondansetron (Zofran)** → mainly blocks 5-HT<sub>3</sub> receptors on intestinal vagal and spinal afferent nerves; also blocks 5-HT<sub>3</sub> receptors in the vomiting center and CTZ.
  - Effective in treating emesis mediated through vagal stimulation (e.g., chemotherapy and postoperative nausea/vomiting)
  - May be combined with corticosteroid (i.e., dexamethasone) for enhanced effects in chemotherapy
  - Side Effects: headache, dizziness, prolongation of QT-interval



## Phenothiazines

- Prochlorperazine (Compazine) and Promethazine (Phenergan)
  - block D<sub>2</sub>, M<sub>1</sub>, and H<sub>1</sub> receptors in CTZ and vomiting center
- Side Effects: extrapyramidal symptoms (EPS), hypotension, sedation (d/t antihistaminic property)
  - EPS is treated with diphenhydramine (Benadryl) 25 mg IV or IM

## Benzamides

- Metoclopramide (Reglan) and Trimethobenzamide (Tigan)
  - block D<sub>2</sub> receptors
  - stimulate cholinergic receptors on GI smooth muscle → increases GI motility (Prokinetic)
  - increases lower esophageal sphincter (LES) tone (tx: GERD)
- Side Effects: anxiety, restlessness, EPS (due to CNS dopamine blocking effects)

## Antihistamines

- Diphenhydramine (Benadryl) 25-50 mg PO/IV/IM Q6H and Dimenhydrinate (Dramamine) 50 mg PO Q4H → 1<sup>st</sup> generation antihistamines → block H<sub>1</sub> receptors with potent anticholinergic properties (SE: dizziness, sedation, dry mouth, blurred vision, urinary retention, etc...)
  - H<sub>1</sub> blocking effect → prevents motion sickness and vertigo (d/t vestibular dysfunction)
- Meclizine (Antivert) 25-50 mg PO Q24H → blocks H<sub>1</sub> receptors with minimal anticholinergic properties (less sedation) → prevents motion sickness and vertigo



## Anticholinergic Drugs

- Scopolamine (Transderm Scop) → highly effective M<sub>1</sub> receptor antagonist for the prevention of motion sickness (vestibular dysfunction)
- Scopolamine Patch: Apply to clear area behind the ear every 72 hours (1.5 mg Q72H)
- Side Effects: anticholinergic adverse effects are minimized d/t localized effects with transdermal application



## Neurokinin-1 (NK<sub>1</sub>) Receptor Antagonists

- Aprepitant (Cinvanti) - PO/IV
  - blocks substance P from binding to NK<sub>1</sub> receptors in vomiting center and CTZ
- Indicated for combination therapy with 5-HT<sub>3</sub> receptor antagonists and corticosteroids for prevention acute and delayed emesis in patients treated with highly-emetogenic chemotherapy agents



## Selection of Antiemetics by Clinical Situation

Situation	Associated neurotransmitters	Recommended antiemetic
Migraine headache	Dopamine (probably a primary mediator)	For headache and nausea: metoclopramide or prochlorperazine
		For nausea: oral antiemetics, metoclopramide, prochlorperazine, serotonin antagonists
Vestibular nausea	Histamine, acetylcholine	Antihistamines and anticholinergics (equally effective)
Pregnancy-induced nausea	Unknown	For nausea: ginger, vitamin B6
		For hyperemesis gravidarum: promethazine (first-line agent); serotonin antagonists and corticosteroids (second-line agents)
Gastroenteritis	Dopamine, serotonin	First-line agents: dopamine antagonists
		Second-line agents: serotonin antagonists
		Use in children is controversial
Postoperative nausea and vomiting	Dopamine, serotonin	Prevention: serotonin antagonists, droperidol, dexamethasone
		Treatment: dopamine antagonists, serotonin antagonists, dexamethasone

*Adapted from: Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004; 69:1169.*